Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Vemurafenib in BRAF Positive Juvenile Refractory Histiocytosis
NCT04943198Phase 2Active, not recruiting
- Start
- Apr 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vemurafenib in histiocytosis (2 arms). Primary endpoint: Event-Free Survival at 2 years. Started Apr 2021; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
histiocytosis
Beyond the preview
Go deeper on NCT04943198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943198.